PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today the very first presentation of results for Opdivo in the cohort of patients along with metastatic urothelial cancer (n=78), the most common sort of bladder cancer, after platinum-based therapy from CheckMate -032, a Phase 1/2 open-label trial. In the trial, the primary endpoint of investigator-assessed confirmed goal response fee (ORR), was 24.4% (95% CI: 15.3-35.4) in patients treated along with Opdivo, along with a minimum follow-up of nine months. Response rates by tumor PD-L1 expression, evaluated as an exploratory endpoint, were similar regardless of PD-L1 expression levels. In patients along with PD-L1 <1%, the ORR was 26.8%, and in patients along with PD-L1 ≥1%, the ORR was 24%. At one year, patients treated along with Opdivo had an overall survival (OS, a secondary endpoint) fee of 45.6%, along with a median OS of 9.72 months (95% CI: 7.26-16.16). The safety profile of Opdivo in CheckMate -032 was consistent along with the known safety profile of Opdivo in others tumor types.
These data will certainly be presented today, Sunday, June 5, at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in an oral abstract session from 8:12 AM – 8:24 AM CDT (Abstract #4501).
Padmanee Sharma, M.D., Ph.D., study investigator and professor at The University of Texas MD Anderson Cancer Center, commented, “Urothelial carcinoma is the most common sort of bladder cancer, accounting for approximately 90% of bladder cancer cases. Patients along with advanced stages of the ailment face higher rates of ailment recurrence and progression, making brand-new research an really essential factor to address this higher unmet medical need. We are pleased along with the findings from the Phase 1/2 study, CheckMate -032, which give support for further study of Opdivo in patients along with this cancer to assess outcomes and survival.”
Bladder cancer is the ninth most typically diagnosed cancer in the world, along with an estimated 430,000 brand-new cases diagnosed per year and over 165,000 deaths per year. The majority of bladder cancers are diagnosed at an early stage, however rates of recurrence and progression are high, and approximately 78% of patients will certainly experience a recurrence within 5 years. Survival rates vary depending on the stage and sort of the cancer and as quickly as it is diagnosed. For Stage IV bladder cancer, the five-year survival fee is 15%.
Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb, commented, “We are excited to present for the very first time results for Opdivo in previously treated metastatic urothelial cancer, a sort of bladder cancer. We are encouraged by the response rates and overall survival data observed along with Opdivo in CheckMate -032, which supports the ongoing Phase 2 study in this cancer. Through our Immuno-Oncology research across different tumor types, our target is to advice a lot more patients achieve quality long-term survival, and we look forward to further study of our Immuno-Oncology agents, including the Opdivo and Yervoy combination, in advanced bladder cancer.”
About CheckMate -032
CheckMate -032 is an ongoing Phase 1/2 open-label trial, evaluating the safety and efficacy of Opdivo monotherapy, or Opdivo combined along with Yervoy in advanced or metastatic durable tumors. The trial enrolled patients regardless of PD-L1 expression. The primary endpoint was investigator-assessed confirmed goal response fee (ORR). Secondary endpoints included safety, duration of response, overall survival (OS) and progression-free survival (PFS).
Data presented at ASCO personal to metastatic or locally advanced urothelial cancer were from a cohort of 78 patients that have actually received one or a lot more prior lines of platinum-based therapy. In this analysis, patients received Opdivo monotherapy (3 mg/kg administered intravenously every two weeks) until progression or discontinuation. Patients treated along with Opdivo monotherapy were allowed to keep on treatment beyond progression if Opdivo was tolerated and clinical benefit was noted, or patients could cross over to receive the combination of Opdivo and Yervoy if they met prespecified criteria.
In the trial, the investigator-assessed confirmed ORR was 24.4% (95% CI: 15.3-35.4) for the cohort of patients treated along with Opdivo. Median duration of response was not estimable (9.92-NE). In addition, the one-year OS fee reported for the Opdivo-cohort was 45.6%, based on Kaplan-Meier estimates, along with a median OS of 9.72 months (95% CI: 7.26-16.16). Median PFS was 2.78 months (95% CI: 1.45-5.85).
Of randomized patients, 67 patients had quantifiable tumor PD-L1 expression, along with 37.3% expressing PD-L1 at ≥1%. goal response fee was 26.8% (14.2-42.9) in patients along with PD-L1 <1%, and 24% (9.4-45.1) in patients along with PD-L1 ≥1%. Efficacy of Opdivo by PD-L1 expression was an exploratory endpoint in CheckMate -032.
The safety profile of Opdivo in CheckMate -032 was consistent along with the known safety profile of Opdivo in others tumor types. Grade 3-4 treatment-related edge events (AEs) occurred in 22% of patients receiving Opdivo, along with the most frequent AEs of any sort of grade reported in ≥10% of patients being fatigue (36%), pruritus (30%), maculopapular rash (18%), increased lipase (14%), nausea (13%), arthralgia (12%), and anemia (10%). Two Grade 5 treatment-related AEs occurred in patients treated along with Opdivo (pneumonitis [n=1] and thrombocytopenia [n=1]). No Grade 3 or 4 pneumonitis or thrombocytopenia was reported.
Bristol-Myers Squibb & Immuno-Oncology: Advancing Oncology Research
At Bristol-Myers Squibb, we have actually a vision for the future of cancer care that is focused on Immuno-Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer.
We have actually a comprehensive clinical portfolio of investigational and approved Immuno-Oncology agents, lots of of which were discovered and made by our scientists. Our ongoing Immuno-Oncology clinical program is looking at broad patient populations, across multiple durable tumors and hematologic malignancies, and lines of therapy and histologies, along with the intent of powering our trials for overall survival and others essential measures enjoy durability of response. We pioneered the research leading to the very first regulatory approval for the combination of two Immuno-Oncology agents, and keep on to study the role of combinations in cancer.
We are likewise investigating others immune system pathways in the treatment of cancer including CTLA-4, CD-137, KIR, SLAMF7, PD-1, GITR, CSF1R, IDO, and LAG-3. These pathways could lead to potential brand-new treatment choices – in combination or monotherapy – to advice patients fight different types of cancers.
Our collaboration along with academia, as well as small and large biotech companies, to research the potential of Immuno-Oncology and non-Immuno-Oncology combinations, helps achieve our target of providing brand-new treatment choices in clinical practice.
At Bristol-Myers Squibb, we are committed to changing survival expectations in hard-to-treat cancers and the means patients live along with cancer.
About Opdivo
Cancer cells could exploit “regulatory” pathways, such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. Opdivo is a PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells, and blocks the binding of PD-L1 and PD-L2, preventing the PD-1 pathway’s suppressive signaling on the immune system, including the interference along with an anti-tumor immune response.
Opdivo’s broad global development program is based on Bristol-Myers Squibb’s discovering of the biology behind Immuno-Oncology. Our company is at the forefront of researching the potential of Immuno-Oncology to extend survival in hard-to-treat cancers. This scientific expertise serves as the basis for the Opdivo development program, which entails a broad range of Phase 3 clinical trials evaluating overall survival as the primary endpoint across a variety of tumor types. The Opdivo trials have actually likewise contributed toward the clinical and scientific discovering of the role of biomarkers and exactly how patients could benefit from Opdivo across the continuum of PD-L1 expression. To date, the Opdivo clinical development program has actually enrolled a lot more compared to 18,000 patients.
Opdivo was the very first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere worldwide in July 2014, and currently has actually regulatory approval in 51 countries including the United States, Japan, and in the European Union.
U.S. FDA APPROVED INDICATIONS FOR OPDIVO®
OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients along with BRAF V600 wild-type unresectable or metastatic melanoma.
OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients along with BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication might be contingent upon verification and description of clinical benefit in confirmatory trials.
OPDIVO® (nivolumab), in combination along with YERVOY® (ipilimumab), is indicated for the treatment of patients along with unresectable or metastatic melanoma. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication might be contingent upon verification and description of clinical benefit in the confirmatory trials.
OPDIVO® (nivolumab) is indicated for the treatment of patients along with metastatic non-small cell lung cancer (NSCLC) along with progression on or after platinum-based chemotherapy. Patients along with EGFR or ALK genomic tumor aberrations ought to have actually ailment progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
OPDIVO® (nivolumab) is indicated for the treatment of patients along with advanced renal cell carcinoma (RCC) that have actually received prior anti-angiogenic therapy.
OPDIVO® (nivolumab) is indicated for the treatment of patients along with classical Hodgkin lymphoma (cHL) that has actually relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post- transplantation brentuximab vedotin. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication might be contingent upon verification and description of clinical benefit in confirmatory trials.
Please refer to the end of the essential Safety Post for a brief description of the patient populations studied in the Checkmate trials.
IMPORTANT SAFETY INFORMATION
WARNING: IMMUNE-MEDIATED edge REACTIONS
YERVOY can easily result in severe and fatal immune-mediated edge reactions. These immune- mediated reactions could involve any sort of organ system; however, the most common severe immune- mediated edge reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested throughout treatment; however, a minority occurred weeks to months after discontinuation of YERVOY.
Assess patients for signs and symptoms of enterocolitis, dermatitis, neuropathy, and endocrinopathy and evaluate clinical chemistries including liver function examinations (LFTs), adrenocorticotropic hormone (ACTH) level, and thyroid function examinations at baseline and prior to each dose.
Permanently discontinue YERVOY and initiate systemic high-dose corticosteroid therapy for severe immune-mediated reactions.
Immune-Mediated Pneumonitis
Immune-mediated pneumonitis, including fatal cases, occurred along with OPDIVO treatment. Across the clinical trial experience along with durable tumors, fatal immune-mediated pneumonitis occurred along with OPDIVO. In addition, in Checkmate 069, there were 6 patients that died free of resolution of abnormal respiratory findings. Monitor patients for signs along with radiographic imaging and symptoms of pneumonitis. Administer corticosteroids for Grade 2 or higher pneumonitis. Completely discontinue for Grade 3 or 4 and withhold until resolution for Grade 2. In Checkmate 069 and 067, immune-mediated pneumonitis occurred in 6% (25/407) of patients receiving OPDIVO along with YERVOY: Fatal (n=1), Grade 3 (n=6), Grade 2 (n=17), and Grade 1 (n=1). In Checkmate 037, 066, and 067, immune-mediated pneumonitis occurred in 1.8% (14/787) of patients receiving OPDIVO: Grade 3 (n=2) and Grade 2 (n=12). In Checkmate 057, immune- mediated pneumonitis, including interstitial lung disease, occurred in 3.4% (10/287) of patients: Grade 3 (n=5), Grade 2 (n=2), and Grade 1 (n=3). In Checkmate 025, pneumonitis, including interstitial lung disease, occurred in 5% (21/406) of patients receiving OPDIVO and 18% (73/397) of patients receiving everolimus. Immune-mediated pneumonitis occurred in 4.4% (18/406) of patients receiving OPDIVO: Grade 4 (n=1), Grade 3 (n=4), Grade 2 (n=12), and Grade 1 (n=1). In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 4.9% (13/263) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 3.4% (9/263) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 2 (n=8).
Immune-Mediated Colitis
Immune-mediated colitis can easily occur along with OPDIVO treatment. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 (of a lot more compared to 5 days duration), 3, or 4 colitis. As a single agent, withhold OPDIVO for Grade 2 or 3 and Completely discontinue for Grade 4 or recurrent colitis upon restarting OPDIVO. as quickly as administered along with YERVOY, withhold OPDIVO for Grade 2 and Completely discontinue for Grade 3 or 4 or recurrent colitis upon restarting OPDIVO. In Checkmate 069 and 067, diarrhea or colitis occurred in 56% (228/407) of patients receiving OPDIVO along with YERVOY. Immune-mediated colitis occurred in 26% (107/407) of patients: Grade 4 (n=2), Grade 3 (n=60), Grade 2 (n=32), and Grade 1 (n=13). In Checkmate 037, 066, and 067, diarrhea or colitis occurred in 31% (242/787) of patients receiving OPDIVO. Immune-mediated colitis occurred in 4.1% (32/787) of patients: Grade 3 (n=20), Grade 2 (n=10), and Grade 1 (n=2). In Checkmate 057, diarrhea or colitis occurred in 17% (50/287) of patients receiving OPDIVO. Immune-mediated colitis occurred in 2.4% (7/287) of patients: Grade 3 (n=3), Grade 2 (n=2), and Grade 1 (n=2). In Checkmate 025, diarrhea or colitis occurred in 25% (100/406) of patients receiving OPDIVO and 32% (126/397) of patients receiving everolimus. Immune-mediated diarrhea or colitis occurred in 3.2% (13/406) of patients receiving OPDIVO: Grade 3 (n=5), Grade 2 (n=7), and Grade 1 (n=1). In Checkmate 205 and 039, diarrhea or colitis occurred in 30% (80/263) of patients receiving OPDIVO. Immune-mediated diarrhea (Grade 3) occurred in 1.1% (3/263) of patients.
In a divide Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal (diarrhea of ≥7 stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) patients. Across every one of YERVOY-treated patients in that study (n=511), 5 (1%) made intestinal perforation, 4 (0.8%) died as a result of complications, and 26 (5%) were hospitalized for severe enterocolitis.
Immune-Mediated Hepatitis
Immune-mediated hepatitis can easily occur along with OPDIVO treatment. Monitor patients for abnormal liver examinations prior to and periodically throughout treatment. Administer corticosteroids for Grade 2 or higher transaminase elevations. Withhold for Grade 2 and Completely discontinue for Grade 3 or 4 immune- mediated hepatitis. In Checkmate 069 and 067, immune-mediated hepatitis occurred in 13% (51/407) of patients receiving OPDIVO along with YERVOY: Grade 4 (n=8), Grade 3 (n=37), Grade 2 (n=5), and Grade 1 (n=1). In Checkmate 037, 066, and 067, immune-mediated hepatitis occurred in 2.3% (18/787) of patients receiving OPDIVO: Grade 4 (n=3), Grade 3 (n=11), and Grade 2 (n=4). In Checkmate 057, one patient (0.3%) made immune-mediated hepatitis. In Checkmate 025, there was an increased incidence of liver test abnormalities compared to baseline in AST (33% vs 39%), alkaline phosphatase (32% vs 32%), ALT (22% vs 31%), and total bilirubin (9% vs 3.5%) in the OPDIVO and everolimus arms, respectively. Immune-mediated hepatitis requiring systemic immunosuppression occurred in 1.5% (6/406) of patients receiving OPDIVO: Grade 3 (n=5) and Grade 2 (n=1). In Checkmate 205 and 039, hepatitis occurred in 11% (30/263) of patients receiving OPDIVO. Immune-mediated hepatitis occurred in 3.4% (9/263): Grade 3 (n=7) and Grade 2 (n=2).
In a divide Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations >5x the ULN or total bilirubin elevations >3x the ULN; Grade 3-5) occurred in 8 (2%) patients, along with fatal hepatic failure in 0.2% and hospitalization in 0.4%.
Immune-Mediated Dermatitis
In a divide Phase 3 study of YERVOY 3 mg/kg, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) patients. 1 (0.2%) patient died as a result of toxic epidermal necrolysis. 1 additional patient called for hospitalization for severe dermatitis.
Immune-Mediated Neuropathies
In a divide Phase 3 study of YERVOY 3 mg/kg, 1 case of fatal Guillain-Barré syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.
Immune-Mediated Endocrinopathies
Hypophysitis, adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus can easily occur along with OPDIVO treatment. Monitor patients for signs and symptoms of hypophysitis, signs and symptoms of adrenal insufficiency throughout and after treatment, thyroid function prior to and periodically throughout treatment, and hyperglycemia. Administer corticosteroids for Grade 2 or higher hypophysitis. Withhold for Grade 2 or 3 and Completely discontinue for Grade 4 hypophysitis. Administer corticosteroids for Grade 3 or 4 adrenal insufficiency. Withhold for Grade 2 and Completely discontinue for Grade 3 or 4 adrenal insufficiency. Administer hormone-alternative therapy for hypothyroidism. Initiate medical management for regulate of hyperthyroidism. Administer insulin for type 1 diabetes. Withhold OPDIVO for Grade 3 and Completely discontinue for Grade 4 hyperglycemia.
In Checkmate 069 and 067, hypophysitis occurred in 9% (36/407) of patients receiving OPDIVO along with YERVOY: Grade 3 (n=8), Grade 2 (n=25), and Grade 1 (n=3). In Checkmate 037, 066, and 067, hypophysitis occurred in 0.9% (7/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=3), and Grade 1 (n=2). In Checkmate 025, hypophysitis occurred in 0.5% (2/406) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 1 (n=1). In Checkmate 069 and 067, adrenal insufficiency occurred in 5% (21/407) of patients receiving OPDIVO along with YERVOY: Grade 4 (n=1), Grade 3 (n=7), Grade 2 (n=11), and Grade 1 (n=2). In Checkmate 037, 066, and 067, adrenal insufficiency occurred in 1% (8/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=5), and Grade 1 (n=1). In Checkmate 057, 0.3% (1/287) of OPDIVO-treated patients made adrenal insufficiency. In Checkmate 025, adrenal insufficiency occurred in 2.0% (8/406) of patients receiving OPDIVO: Grade 3 (n=3), Grade 2 (n=4), and Grade 1 (n=1). In Checkmate 205 and 039, adrenal insufficiency (Grade 2) occurred in 0.4% (1/263) of patients receiving OPDIVO. In Checkmate 069 and 067, hypothyroidism or thyroiditis occurred in 22% (89/407) of patients receiving OPDIVO along with YERVOY: Grade 3 (n=6), Grade 2 (n=47), and Grade 1 (n=36). Hyperthyroidism occurred in 8% (34/407) of patients: Grade 3 (n=4), Grade 2 (n=17), and Grade 1 (n=13). In Checkmate 037, 066, and 067, hypothyroidism or thyroiditis occurred in 9% (73/787) of patients receiving OPDIVO: Grade 3 (n=1), Grade 2 (n=37), Grade 1 (n=35). Hyperthyroidism occurred in 4.4% (35/787) of patients receiving OPDIVO: Grade 3 (n=1), Grade 2 (n=12), and Grade 1 (n=22). In Checkmate 057, Grade 1 or 2 hypothyroidism, including thyroiditis, occurred in 7% (20/287) and elevated thyroid stimulating hormone occurred in 17% of patients receiving OPDIVO. Grade 1 or 2 hyperthyroidism occurred in 1.4% (4/287) of patients. In Checkmate 025, thyroid ailment occurred in 11% (43/406) of patients receiving OPDIVO, including one Grade 3 event, and in 3.0% (12/397) of patients receiving everolimus. Hypothyroidism/thyroiditis occurred in 8% (33/406) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=17), and Grade 1 (n=14). Hyperthyroidism occurred in 2.5% (10/406) of patients receiving OPDIVO: Grade 2 (n=5) and Grade 1 (n=5). In Checkmate 205 and 039, hypothyroidism/thyroiditis occurred in 12% (32/263) of patients receiving OPDIVO: Grade 2 (n=18) and Grade 1: (n=14). Hyperthyroidism occurred in 1.5% (4/263) of patients receiving OPDIVO: Grade 2: (n=3) and Grade 1 (n=1). In Checkmate 069 and 067, diabetes mellitus or diabetic ketoacidosis occurred in 1.5% (6/407) of patients: Grade 4 (n=3), Grade 3 (n=1), Grade 2 (n=1), and Grade 1 (n=1). In Checkmate 037, 066, and 067, diabetes mellitus or diabetic ketoacidosis occurred in 0.8% (6/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=3), and Grade 1 (n=1). In Checkmate 025, hyperglycemic edge events occurred in 9% (37/406) patients.
Diabetes mellitus or diabetic ketoacidosis occurred in 1.5% (6/406) of patients receiving OPDIVO: Grade 3 (n=3), Grade 2 (n=2), and Grade 1 (n=1). In Checkmate 205 and 039, diabetes mellitus occurred in 0.8% (2/263) of patients receiving OPDIVO: Grade 3 (n=1) and Grade 1 (n=1).
In a divide Phase 3 study of YERVOY 3 mg/kg, severe to life-threatening immune-mediated endocrinopathies (requiring hospitalization, urgent medical intervention, or interfering along with activities of day-to-day living; Grade 3-4) occurred in 9 (1.8%) patients. every one of 9 patients had hypopituitarism, and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism. 6 of the 9 patients were hospitalized for severe endocrinopathies.
Immune-Mediated Nephritis and Renal Dysfunction
Immune-mediated nephritis can easily occur along with OPDIVO treatment. Monitor patients for elevated serum creatinine prior to and periodically throughout treatment. For Grade 2 or 3 increased serum creatinine, withhold and administer corticosteroids; if worsening or no improvement occurs, Completely discontinue. Administer corticosteroids for Grade 4 serum creatinine elevation and Completely discontinue. In Checkmate 069 and 067, immune-mediated nephritis and renal dysfunction occurred in 2.2% (9/407) of patients: Grade 4 (n=4), Grade 3 (n=3), and Grade 2 (n=2). In Checkmate 037, 066, and 067, nephritis and renal dysfunction of any sort of grade occurred in 5% (40/787) of patients receiving OPDIVO. Immune-mediated nephritis and renal dysfunction occurred in 0.8% (6/787) of patients: Grade 3 (n=4) and Grade 2 (n=2). In Checkmate 057, Grade 2 immune-mediated renal dysfunction occurred in 0.3% (1/287) of patients receiving OPDIVO. In Checkmate 025, renal injury occurred in 7% (27/406) of patients receiving OPDIVO and 3.0% (12/397) of patients receiving everolimus. Immune-mediated nephritis and renal dysfunction occurred in 3.2% (13/406) of patients receiving OPDIVO: Grade 5 (n=1), Grade 4 (n=1), Grade 3 (n=5), and Grade 2 (n=6). In Checkmate 205 and 039, nephritis and renal dysfunction occurred in 4.9% (13/263) of patients treated along with OPDIVO. This included one reported case (0.3%) of Grade 3 autoimmune nephritis.
Immune-Mediated Rash
Immune-mediated rash can easily occur along with OPDIVO treatment. Severe rash (including rare cases of fatal toxic epidermal necrolysis) occurred in the clinical program of OPDIVO. Monitor patients for rash. Administer corticosteroids for Grade 3 or 4 rash. Withhold for Grade 3 and Completely discontinue for Grade 4. In Checkmate 069 and 067, immune-mediated rash occurred in 22.6% (92/407) of patients receiving OPDIVO along with YERVOY: Grade 3 (n=15), Grade 2 (n=31), and Grade 1 (n=46). In Checkmate 037, 066, and 067, immune-mediated rash occurred in 9% (72/787) of patients receiving OPDIVO: Grade 3 (n=7), Grade 2 (n=15), and Grade 1 (n=50). In Checkmate 057, immune-mediated rash occurred in 6% (17/287) of patients receiving OPDIVO including four Grade 3 cases. In Checkmate 025, rash occurred in 28% (112/406) of patients receiving OPDIVO and 36% (143/397) of patients receiving everolimus. Immune- mediated rash, defined as a rash treated along with systemic or topical corticosteroids, occurred in 7% (30/406) of patients receiving OPDIVO: Grade 3 (n=4), Grade 2 (n=7), and Grade 1 (n=19). In Checkmate 205 and 039, rash occurred in 22% (58/263) of patients receiving OPDIVO. Immune-mediated rash occurred in 7% (18/263) of patients on OPDIVO: Grade 3 (n=4), Grade 2 (n=3), and Grade 1 (n=11).
Immune-Mediated Encephalitis
Immune-mediated encephalitis can easily occur along with OPDIVO treatment. Withhold OPDIVO in patients along with new-onset moderate to severe neurologic signs or symptoms and evaluate to rule out others causes. If others etiologies are ruled out, administer corticosteroids and Completely discontinue OPDIVO for immune-mediated encephalitis. In Checkmate 067, encephalitis was identified in one patient (0.2%) receiving OPDIVO along with YERVOY. In Checkmate 057, fatal limbic encephalitis occurred in one patient (0.3%) receiving OPDIVO. In Checkmate 205 and 039, encephalitis occurred in 0.8% (2/263) of patients after allogeneic HSCT after OPDIVO.
Other Immune-Mediated edge Reactions
Based on the severity of edge reaction, Completely discontinue or withhold treatment, administer high-dose corticosteroids, and, if appropriate, initiate hormone-alternative therapy. In < 1.0% of patients receiving OPDIVO, the adhering to clinically significant, immune-mediated edge reactions occurred: uveitis, iritis, pancreatitis, facial and abducens nerve paresis, demyelination, polymyalgia rheumatica, autoimmune neuropathy, Guillain-Barré syndrome, hypopituitarism, systemic inflammatory response syndrome, gastritis, duodenitis, and sarcoidosis. Across clinical trials of OPDIVO as a single agent administered at doses of 3 mg/kg and 10 mg/kg, additional clinically significant, immune- mediated edge reactions were identified: motor dysfunction, vasculitis, and myasthenic syndrome.
Infusion Reactions
Severe infusion reactions have actually been reported in <1.0% of patients in clinical trials of OPDIVO. Discontinue OPDIVO in patients along with Grade 3 or 4 infusion reactions. Interrupt or slow the fee of infusion in patients along with Grade 1 or 2. In Checkmate 069 and 067, infusion- related reactions occurred in 2.5% (10/407) of patients receiving OPDIVO along with YERVOY: Grade 2 (n=6) and Grade 1 (n=4). In Checkmate 037, 066, and 067, Grade 2 infusion related reactions occurred in 2.7% (21/787) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=8), and Grade 1 (n=11). In Checkmate 057, Grade 2 infusion reactions requiring corticosteroids occurred in 1.0% (3/287) of patients receiving OPDIVO. In Checkmate 025, hypersensitivity/infusion-related reactions occurred in 6% (25/406) of patients receiving OPDIVO and 1.0% (4/397) of patients receiving everolimus. In Checkmate 205 and 039, hypersensitivity/infusion- related reactions occurred in 16% (42/263) of patients receiving OPDIVO: Grade 3 (n=2), Grade 2 (n=24), and Grade 1 (n=16).
Complications of Allogeneic HSCT after OPDIVO
Complications, including fatal events, occurred in patients that received allogeneic HSCT after OPDIVO. Outcomes were evaluated in 17 patients from Checkmate 205 and 039, that underwent allogeneic HSCT after discontinuing OPDIVO (15 along with reduced-intensity conditioning, 2 along with myeloablative conditioning). Thirty-5 percent (6/17) of patients died from complications of allogeneic HSCT after OPDIVO. 5 deaths occurred in the setting of severe or refractory GVHD. Grade 3 or greater acute GVHD was reported in 29% (5/17) of patients. Hyperacute GVHD was reported in 20% (n=2) of patients. A steroid-requiring febrile syndrome, free of an identified infectious cause, was reported in 35% (n=6) of patients. Two cases of encephalitis were reported: Grade 3 (n=1) lymphocytic encephalitis free of an identified infectious cause, and Grade 3 (n=1) suspected viral encephalitis. Hepatic veno-occlusive ailment (VOD) occurred in one patient, that received reduced-intensity conditioned allogeneic SCT and died of GVHD and multi-organ failure. others cases of hepatic VOD after reduced-intensity conditioned allogeneic HSCT have actually likewise been reported in patients along with lymphoma that received a PD-1 receptor blocking antibody prior to transplantation. Cases of fatal hyperacute GVHD have actually likewise been reported. These complications could occur despite intervening therapy between PD-1 blockade and allogeneic HSCT.
Follow patients closely for early evidence of transplant-related complications such as hyperacute GVHD, severe (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic VOD, and others immune- mediated edge reactions, and intervene promptly.
Embryo-fetal Toxicity
Based on their mechanisms of action, OPDIVO and YERVOY can easily induce fetal harm as quickly as administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception throughout treatment along with an OPDIVO- or YERVOY- containing regimen and for at least 5 months after the last dose of OPDIVO.
Lactation
It is not known whether OPDIVO or YERVOY is present in human milk. Since lots of drugs, including antibodies, are excreted in human milk and due to the potential for serious edge reactions in nursing infants from an OPDIVO-containing regimen, advise women to discontinue breastfeeding throughout treatment. Advise women to discontinue nursing throughout treatment along with YERVOY and for 3 months adhering to the last dose.
Serious edge Reactions
In Checkmate 067, serious edge reactions (73% and 37%), edge reactions leading to permanent discontinuation (43% and 14%) or to dosing delays (55% and 28%), and Grade 3 or 4 edge reactions (72% and 44%) every one of occurred a lot more regularly in the OPDIVO plus YERVOY arm relative to the OPDIVO arm. The most frequent (≥10%) serious edge reactions in the OPDIVO plus YERVOY arm and the OPDIVO arm, respectively, were diarrhea (13% and 2.6%), colitis (10% and 1.6%), and pyrexia (10% and 0.6%). In Checkmate 037, serious edge reactions occurred in 41% of patients receiving OPDIVO. Grade 3 and 4 edge reactions occurred in 42% of patients receiving OPDIVO. The most frequent Grade 3 and 4 edge drug reactions reported in 2% to <5% of patients receiving OPDIVO were abdominal pain, hyponatremia, increased aspartate aminotransferase, and increased lipase. In Checkmate 066, serious edge reactions occurred in 36% of patients receiving OPDIVO. Grade 3 and 4 edge reactions occurred in 41% of patients receiving OPDIVO. The most frequent Grade 3 and 4 edge reactions reported in ≥2% of patients receiving OPDIVO were gamma-glutamyltransferase raise (3.9%) and diarrhea (3.4%). In Checkmate 057, serious edge reactions occurred in 47% of patients receiving OPDIVO. The most frequent serious edge reactions reported in ≥2% of patients were pneumonia, pulmonary embolism, dyspnea, pleural effusion, and respiratory failure. In Checkmate 025, serious edge reactions occurred in 47% of patients receiving OPDIVO. The most frequent serious edge reactions reported in ≥2% of patients were acute kidney injury, pleural effusion, pneumonia, diarrhea, and hypercalcemia. In Checkmate 205 and 039, among every one of patients (safety population [n=263]), edge reactions leading to discontinuation (4.2%) or to dosing delays (23%) occurred. The most frequent serious edge reactions reported in ≥1% of patients were infusion-related reaction, pneumonia, pleural effusion, pyrexia, rash and pneumonitis. Ten patients died from sets off others compared to ailment progression, including 6 that died from complications of allogeneic HSCT. Serious edge reactions occurred in 21% of patients in the safety population (n=263) and 27% of patients in the subset of patients evaluated for efficacy (efficacy population [n=95]).
Common edge Reactions
In Checkmate 067, the most common (≥20%) edge reactions in the OPDIVO plus YERVOY arm were fatigue (59%), rash (53%), diarrhea (52%), nausea (40%), pyrexia (37%), vomiting (28%), and dyspnea (20%). The most common (≥20%) edge reactions in the OPDIVO arm were fatigue (53%), rash (40%), diarrhea (31%), and nausea (28%). In Checkmate 037, the most common edge reaction (≥20%) reported along with OPDIVO was rash (21%). In Checkmate 066, the most common edge reactions (≥20%) reported along with OPDIVO vs dacarbazine were fatigue (49% vs 39%), musculoskeletal pain (32% vs 25%), rash (28% vs 12%), and pruritus (23% vs 12%). In Checkmate 057, the most common edge reactions (≥20%) reported along with OPDIVO were fatigue (49%), musculoskeletal pain (36%), cough (30%), decreased cravings (29%), and constipation (23%). In Checkmate 025, the most common edge reactions (≥20%) reported in patients receiving OPDIVO vs everolimus were asthenic conditions (56% vs 57%), cough (34% vs 38%), nausea (28% vs 29%), rash (28% vs 36%), dyspnea (27% vs 31%), diarrhea (25% vs 32%), constipation (23% vs 18%), decreased cravings (23% vs 30%), spine pain (21% vs 16%), and arthralgia (20% vs 14%). In Checkmate 205 and 039, among every one of patients (safety population [n=263]) and the subset of patients in the efficacy population (n=95), respectively, the most common edge reactions (reported in at least 20%) were fatigue (32% and 43%), upper respiratory tract infection (28% and 48%), pyrexia (24% and 35%), diarrhea (23% and 30%), and cough (22% and 35%). In the subset of patients in the efficacy population (n=95), the most common edge reactions likewise included rash (31%), musculoskeletal pain (27%), pruritus (25%), nausea (23%), arthralgia (21%), and peripheral neuropathy (21%).
In a divide Phase 3 study of YERVOY 3 mg/kg, the most common edge reactions (≥5%) in patients that received YERVOY at 3 mg/kg were fatigue (41%), diarrhea (32%), pruritus (31%), rash (29%), and colitis (8%).
CHECKMATE Trials and Patient Populations
Checkmate 069 and 067 – advanced melanoma alone or in combination along with YERVOY; Checkmate 037 and 066 – advanced melanoma; Checkmate 057 – non-squamous non-small cell lung cancer (NSCLC); Checkmate 025 – renal cell carcinoma; Checkmate 205/039 – classical Hodgkin lymphoma
About the Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Collaboration
In 2011, through a collaboration agreement along with Ono Pharmaceutical Co., Ltd (Ono) Bristol-Myers Squibb expanded its territorial rights to create and commercialize Opdivo globally except in Japan, South Korea and Taiwan, where Ono had retained every one of rights to the compound at the time. On July 23, 2014, Bristol-Myers Squibb and Ono further expanded the companies’ strategic collaboration agreement to jointly create and commercialize multiple immunotherapies – as single agents and combination regimens – for patients along with cancer in Japan, South Korea and Taiwan.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, create and deliver innovative medicines that advice patients prevail over serious diseases. For a lot more Post Concerning Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube and Facebook.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 concerning the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or modification any sort of of them, and could induce actual outcomes and results to differ materially from current expectations. No forward-looking statement can easily be guaranteed. Among others risks, there can easily be no make certain that Opdivo will certainly receive regulatory approval for the additional indication described herein. Forward-looking statements in this press release ought to be evaluated with each other along with the lots of uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2015 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any sort of forward-looking statement, whether as a result of brand-new information, future events or otherwise.
